Compounds > lhrh, leu(6)-n-et-glynh2(10)-
Page last updated: 2024-12-07

lhrh, leu(6)-n-et-glynh2(10)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID126336
MeSH IDM0059407

Synonyms (6)

Synonym
lhrh, leu(6)-n-et-glynh2(10)-
6-leu-10-n-et-glynh2-lhrh
gnrh, leu(6)-n-et-glynh2(10)-
leu-lhrh-ea
71779-20-9
lhrh, leucyl(6)-n-ethylglycinamide(10)-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Using various dosing regimens and routes of administration in animal experiments and in clinical trials, these peptides invariably produce paradoxical inhibitory effects on reproductive function."( Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men.
Faure, N; Lemay, A, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.11 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycolic acid
glycolic acid: RN given refers to parent cpd. glycolic acid : A 2-hydroxy monocarboxylic acid that is acetic acid where the methyl group has been hydroxylated.		1.97102-hydroxy monocarboxylic acid;
primary alcohol		keratolytic drug;
metabolite
buserelin
Buserelin: A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications.		2.3720oligopeptide
lhrh, n-et-alanh2(6)-
[no description available]		1.9510
trelstar
Triptorelin Pamoate: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.		1.9610
lhrh, phe(2)-trp(3)-phe(6)-
LHRH, Phe(2)-Trp(3)-Phe(6)-: gonodorelin antagonist; RN given refers to (D-Phe-D-Trp-D-Phe)-isomer		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
48,XXYY Syndrome
[description not available]		01.9510
Klinefelter Syndrome
A form of male HYPOGONADISM, characterized by the presence of an extra X CHROMOSOME, small TESTES, seminiferous tubule dysgenesis, elevated levels of GONADOTROPINS, low serum TESTOSTERONE, underdeveloped secondary sex characteristics, and male infertility (INFERTILITY, MALE). Patients tend to have long legs and a slim, tall stature. GYNECOMASTIA is present in many of the patients. The classic form has the karyotype 47,XXY. Several karyotype variants include 48,XXYY; 48,XXXY; 49,XXXXY, and mosaic patterns ( 46,XY/47,XXY; 47,XXY/48,XXXY, etc.).		01.9510
Foreign-Body Reaction
Chronic inflammation and granuloma formation around irritating foreign bodies.		01.9710
Cancer of Prostate
[description not available]		01.9610
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9610